SCHEMBL3308918

SCHEMBL3308918

CCOC(=O)C1CCC=CCCCCCN(Cc2ccc(OC)cc2)C(=O)[N+]2CC(Oc3cc(OC)nc(-c4ccccc4)n3)CC2C(=O)N1

nearest known ligand 0.35

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MCHR1 Q99705 6/20 0.35
▸ KCNH2 Q12809 6/20 0.35
▸ NPSR1 Q6W5P4 3/20 0.32
▸ ALDH1A1 P00352 3/20 0.32
▸ MAPT P10636 2/20 0.32
▸ KDM4E B2RXH2 1/20 0.32
▸ HPGD P15428 1/20 0.32
▸ TSHR P16473 1/20 0.32
▸ HSD17B10 Q99714 1/20 0.32
▸ ATM Q13315 1/20 0.32
▸ L3MBTL1 Q9Y468 1/20 0.32
▸ MEN1 O00255 1/20 0.31
▸ HTT P42858 1/20 0.31
▸ KMT2A Q03164 1/20 0.31
▸ SMN1; SMN2 Q16637 1/20 0.31
▸ HRH3 Q9Y5N1 1/20 0.31
▸ CYP3A4 P08684 1/20 0.31
▸ CYP2D6 P10635 1/20 0.31
▸ CYP2C9 P11712 1/20 0.31
▸ CYP2C19 P33261 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3308959 0.93 KCNH2 (0.36) MCHR1KCNH2NPSR1MEN1HTT
SCHEMBL3314022 0.91 ALDH1A1 (0.32) MCHR1KCNH2NPSR1ALDH1A1MAPT
SCHEMBL2839916 0.87 ALDH1A1 (0.33) MCHR1KCNH2NPSR1ALDH1A1MAPT
SCHEMBL3309953 0.84 CTSB (0.33) MCHR1KCNH2NPSR1MEN1HTT
SCHEMBL3526341 0.82 ALDH1A1 (0.34) MCHR1KCNH2ALDH1A1KDM4EL3MBTL1
SCHEMBL995887 0.82 ALDH1A1 (0.36) ALDH1A1KDM4ETSHRL3MBTL1HRH3
SCHEMBL996970 0.82 MCHR1 (0.33) MCHR1KCNH2ALDH1A1MAPTKDM4E
SCHEMBL2837719 0.81 KCNH2 (0.31) MCHR1KCNH2
SCHEMBL994826 0.79 ALDH1A1 (0.35) KCNH2ALDH1A1MAPTKDM4EHSD17B10
SCHEMBL995145 0.77 MMP1 (0.34) ALDH1A1KDM4EL3MBTL1MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2118091-B1 PYRIMIDINE SUBSTITUTED MACROCYCLIC HCV INHIBITORS JANSSEN SCIENCES IRELAND UC (IE) 2015-04-15 — — EP disclosed
US-8937080-B2 Pyrimidine substituted macrocyclic HCV inhibitors MEDIVIR AB (SE) 2015-01-20 — — US disclosed
US-20100113440-A1 PYRIMIDINE SUBSTITUTED MACROCYCLIC HCV INHIBITORS TIBOTEC PHARMACEUTICALS, LTD. (IE) 2010-05-06 — — US disclosed
EP-2118091-A1 PYRIMIDINE SUBSTITUTED MACROCYCLIC HCV INHIBITORS Tibotec Pharmaceuticals (IE) 2009-11-18 — — EP disclosed
WO-2008095999-A1 PYRIMIDINE SUBSTITUTED MACROCYCLIC HCV INHIBITORS TIBOTEC PHARMACEUTICALS LTD. (IE) 2008-08-14 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100113440-A1 PYRIMIDINE SUBSTITUTED MACROCYCLIC HCV INHIBITORS NUDT1, PNP, SLC28A1 MCHR1 4846/4885KCNH2 4372/4885NPSR1 3354/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback